Back to News
Sep 18, 2025 12:00 PM

Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device.

Benzinga reached out to DexCom for comments and is yet to hear from them.

A surprise FDA inspection found Dexcom made an unauthorized design change to the G7 glucose monitoring device, with internal tests showing worse accuracy across the board.

Despite this, the company sold the device, drawing FDA scrutiny. Executives have since departed as patient complaints climbed, rivals gained share, insiders sold stock, and accounting practices came under question.

Also Read: Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges

Many patients are reverting to the G6 or shifting to competitors, suggesting Dexcom's challenges run deeper than expected.

Reports collected by Hunterbrook include accounts of patients suffering severe consequences from inaccurate G7 readings.

A law firm investigating the device said at ...